Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970151 | 0.89 | KDM1A (0.53) | GRM2KDM1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1549465 | 0.83 | GRM2 (0.50) | GRM2KDM1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12603839 | 0.81 | SMN1; SMN2 (0.61) | GRM2KDM1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12569433 | 0.81 | GRM2 (0.49) | GRM2KDM1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8187876 | 0.81 | GRM2 (0.49) | GRM2KDM1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12002675 | 0.81 | NPC1 (0.61) | KDM1ANPC1RAB9ASMN1; SMN2FYN | |
| SCHEMBL2216313 | 0.81 | FYN (0.56) | KDM1ANPC1RAB9ASMN1; SMN2FYN | |
| SCHEMBL26316729 | 0.81 | AURKA (0.54) | KDM1ANPC1RAB9ASMN1; SMN2FYN | |
| SCHEMBL2412899 | 0.81 | CYP11B1 (0.59) | KDM1ANPC1RAB9ASMN1; SMN2FYN | |
| SCHEMBL4420085 | 0.81 | P2RX7 (0.51) | GRM2KDM1ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| CN-1875002-B | Phenyl derivatives as PPAR agonists | HOFFMANN LA ROCHE | 2011-08-03 | — | — | CN | disclosed |
| EP-2314576-A1 | Phenyl derivatives as PPAR agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| CN-1875002-A | Phenyl derivatives as PPAR agonists | HOFFMANN LA ROCHE (CH) | 2006-12-06 | — | — | CN | disclosed |
| US-7115611-B2 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| CN-1047220-A | PAN GRANULATION | DU PONT (US) | 1990-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | GRM2 1661/4885KDM1A 1272/4885NPC1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.